Kcnn3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KCNN3 (SK3) is a small-conductance calcium-activated potassium channel. It is expressed in various brain regions and regulates neuronal excitability. SK3 is implicated in schizophrenia and migraine. It plays a role in modulating dopamine signaling.
KCNN3 (Potassium Calcium-Activated Channel Subfamily N Member 3) is a gene located on chromosome 4q22 that plays an important role in neurodegenerative disease. Mutations in KCNN3 are associated with Schizophrenia, Neuronal Excitability, Migraine. The gene is catalogued as NCBI Gene ID 3778 and OMIM 609923.
The KCNN3 gene encodes a protein involved in key neuronal functions. It is expressed in Brain, Cortex, Hippocampus.
- Brain, Cortex, Hippocampus
Expression data is available from the Allen Human Brain Atlas.
KCNN3 mutations are linked to the following conditions:
Schizophrenia, Neuronal Excitability, Migraine
The study of Kcnn3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Potassium channels in neurons: Hille B. Ionic Channels of Excitable Membranes. 3rd ed. Sinauer Associates; 2001.
- KCNN channels (SK/IK): Stocker M. Nat Rev Neurosci. 2004;5(10):758-770. PMID:15378036
- KCa channels in neurodegeneration: Shah NH, et al. Nat Rev Neurosci. 2018;19(9):485-498. PMID:30046008
- Potassium channel dysfunction in AD: Angulo E, et al. J Neurosci. 2004;24(20):4676-4682. PMID:15140932
- Potassium channels and neuronal excitability: Bean BP. Nat Rev Neurosci. 2007;8(6):451-465. PMID:17541432
- SK channel activators as therapy: Ehling P, et al. Nat Rev Drug Discov. 2020;19(11):773-789. PMID:32877965
- Potassium channels in PD: Lüscher C, Slesinger PA. Nat Rev Neurosci. 2010;11(9):569-579. PMID:20649637
- Ion channel therapeutics: Garnock-Jones KP. CNS Drugs. 2017;31(5):383-392. PMID:28447065
- Stocker M. Calcium-activated potassium channels: molecular diversity and function. Physiological Reviews. 2004;84(3):903-934. PMID:15269336
- Bhattacharjee A, Kaczmarek LK. Slack channels: from genes to function. Cell Calcium. 2005;38(3-4):237-246. PMID:16102830
- Passmore GM, Reilly JM, Wang Z, et al. Functional analysis of KCa3.1 channel blockers in sensory neurons. European Journal of Pharmacology. 2012;691:28-36. PMID:22705073
- Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nature Reviews Drug Discovery. 2009;8(12):982-1001. PMID:19960002
- Kohler M, Hirschberg B, Bond CT, et al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science. 1996;273(5282):1709-1714. PMID:8781166
- Herson PS, Brody DL, Kaczmarek LK. In quest of the cardiac sK channel. Cardiovascular Research. 1999;42(2):377-385. PMID:10510335
- Mathie A, Wooltorton JR, Watkins CS. Voltage-gated potassium channels as therapeutic targets. CNS Drugs. 1998;9(5):335-346.
- Rudy B, McBain CJ. Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing. Trends in Neurosciences. 2001;24(9):517-526. PMID:11530637